Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Royalty Pharma Plc
Feb 11, 2026
Royalty Pharma Reports Q4 and Full Year 2025 Results
Jan 20, 2026
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Jan 11, 2026
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Jan 9, 2026
Royalty Pharma Announces Dividend Increase
Feb 11, 2026
[10-K] Royalty Pharma plc Files Annual Report
Feb 11, 2026
[8-K] Royalty Pharma plc Reports Material Event
Feb 3, 2026
[144] Royalty Pharma plc SEC Filing
Feb 2, 2026
[144] Royalty Pharma plc SEC Filing
18.82B
387.98M
8.74%
82.44%
3.85%
Biotechnology
Pharmaceutical Preparations
United States
NEW YORK